APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Must have received:

previously treated with at least 1 prior line of therapy

Cannot have received: allogeneic cell transplant

Prior history of allogeneic cell transplant

Cannot have received: adoptive cellular immunotherapy

Exception: allowed if >2 years prior

adoptive cellular immunotherapy within 2 years

Cannot have received: autologous hematopoietic stem cell transplantation

Exception: allowed if >6 months prior

autologous hematopoietic stem cell transplantation within 6 months

Cannot have received: monoclonal antibody therapy

Exception: allowed if >4 weeks prior

Monoclonal antibody therapy within 4 weeks prior to the first dose

Cannot have received: anti-cancer therapy

Exception: allowed if >14 days prior

Received anti-cancer therapy within 14 days prior to the first dose of therapy, including chemotherapy, radiotherapy, immunotherapy or hormone therapy for anti-tumor purposes

Cannot have received: investigational agent

Exception: allowed if >28 days prior

28 days for any investigational agent prior to the first dose of therapy

Cannot have received: BCL-xL inhibitor

Prior exposure to BCL-xL inhibitor